Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eichelbaum

Showing results (181-190 of 263) with videos related to

Pageof 27
Sort By:
Clinical Pharmacology and Therapeutics|March 1, 1987
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizersB Osikowska-Evers, P Dayer, U A Meyer, et al.
Pharmacogenetics|October 1, 1993
Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysisL F Jorge, T D Arias, U Griese, et al.
British Journal of Clinical Pharmacology|April 1, 1987
Evidence for polymorphic oxidation of sparteine in Japanese subjectsT Ishizaki, M Eichelbaum, Y Horai, et al.
Archiv Fur Toxikologie|February 28, 1974
Pharmacokinetics, cardiovascular and metabolic actions of cyclohexylamine in manM Eichelbaum, J H Hengstmann, H D Rost, et al.
Pharmacogenetics|January 14, 2000
Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African populationE U Griese, S Asante-Poku, D Ofori-Adjei, et al.
Pharmacogenetics|October 1, 1996
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reactionT Stüven, E U Griese, H K Kroemer, et al.
DNA and Cell Biology|October 1, 1991
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European populationF Broly, A Gaedigk, M Heim, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteineG Mikus, H R Ha, S Vozeh, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 25, 2000
Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometryU Hofmann, M Pecia, G Heinkele, et al.
Clinical Pharmacology and Therapeutics|June 1, 1984
Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolismR Dahlqvist, L Bertilsson, D J Birkett, et al.
Pageof 27

Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
Clinical Pharmacology and Therapeutics|March 1, 1987
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizersB Osikowska-Evers, P Dayer, U A Meyer, et al.
Pharmacogenetics|October 1, 1993
Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysisL F Jorge, T D Arias, U Griese, et al.
British Journal of Clinical Pharmacology|April 1, 1987
Evidence for polymorphic oxidation of sparteine in Japanese subjectsT Ishizaki, M Eichelbaum, Y Horai, et al.
Archiv Fur Toxikologie|February 28, 1974
Pharmacokinetics, cardiovascular and metabolic actions of cyclohexylamine in manM Eichelbaum, J H Hengstmann, H D Rost, et al.
Pharmacogenetics|January 14, 2000
Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African populationE U Griese, S Asante-Poku, D Ofori-Adjei, et al.
Pharmacogenetics|October 1, 1996
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reactionT Stüven, E U Griese, H K Kroemer, et al.
DNA and Cell Biology|October 1, 1991
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European populationF Broly, A Gaedigk, M Heim, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteineG Mikus, H R Ha, S Vozeh, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 25, 2000
Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometryU Hofmann, M Pecia, G Heinkele, et al.
Clinical Pharmacology and Therapeutics|June 1, 1984
Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolismR Dahlqvist, L Bertilsson, D J Birkett, et al.
Pageof 27